Alnylam to Sell $125M in Stock

Premium

Alnylam Pharmaceuticals this week announced that it will raise $125 million through the public sale of common stock.

The move comes as Alnylam stock is riding at around $19.90 a share, near a 52-week high of $21.38. It also follows the company's recent litigation settlement with one-time partner Tekmira Pharmaceuticals, which called for Alnylam to pay out $65 million to end the dispute (GSN 11/15/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.